AnGes, Inc. (TYO:4563)
25.00
+1.00 (4.17%)
Nov 18, 2026, 10:12 AM JST
AnGes Revenue
AnGes had revenue of 249.00M JPY in the quarter ending September 30, 2026, with 7.33% growth. This brings the company's total for the last twelve months to 979.00M, up 19.68% year-over-year. In the year 2025, AnGes had annual revenue of 874.00M with 35.93% growth. That makes AnGes the 39,333rd largest company in the world by revenue and 3,797th in Japan.
Revenue (ttm)
979.00M
Revenue Growth
+19.68%
P/S Ratio
10.35
Revenue / Employee
17.48M
Employees
56
Market Cap
10.13B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 874.00M | 231.00M | 35.93% |
| Dec 31, 2024 | 643.00M | 491.00M | 323.03% |
| Dec 31, 2023 | 152.00M | 85.00M | 126.87% |
| Dec 31, 2022 | 67.00M | 3.00M | 4.69% |
| Dec 31, 2021 | 64.00M | 25.00M | 64.10% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Kidswell Bio | 5.79B |
| StemCell Institute | 2.81B |
| ReproCELL | 2.42B |
| Immuno-Biological Laboratories | 1.08B |
| Carna Biosciences | 756.57M |
| Nano Holdings | 210.00M |
| ADR Biomedical Holdings | 98.00M |
| Kubota Pharmaceutical Holdings | 12.77M |